In addition to Andrew, Becky Taub, Madrigal Pharmaceuticals co-founder, Director, CMO and President of Research & Development and Dr.Michael Fuchs, Acting Chief of the Division of Gastroenterology and Hepatology and the Central Virginia VA Health Care System, joined Stephen Harrison, Louise Campbell and Roger Green to discuss Global Liver Institute’s US NASH Action Plan. Andrew led a discussion of the plan’s four major focus areas, while the Surfers and guests discussed what they consider key needs and opportunities in each area.

This episode is sponsored with a grant from Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is leading the field of NASH therapeutic development with resmetirom, a thyroid receptor beta agonist with potential to address both the liver pathophysiology and fibrosis caused by NASH.

TOPICS: AASLD, cirrhosis, COVID-19, Diagnostic Tests, Drug Trial, education, FDA, Madrigal, NAFLD, NASH, non-invasive liver testing, Patient Advocacy, PNAFLD,

Surfing The NASH Tsunami is brought to you by HEP Dynamics
#HEPdynamics #SurfingNASH #podcast